Outlook: Progression, partnering and prioritisation
With Xadago (safinamide) now formally approved in Europe this should trigger first royalty income from commercial partner Zambon upon launch, which is initially targeted in Germany. Safinamide in the US is now back on track with an approval decision expected by YE15. A safinamide sub-licensing deal in the US, in addition to partnering NW-3509 are both on the cards. Our valuation is increased to CHF496m (€466m) with a higher safinamide royalty in addition to a risk-adjusted contribution in dyskinesia.Newron Pharmaceuticals is a clinical stage biopharmaceutical company. Co. is focused on the development of drugs for the treatment of central nervous system disorders and pain. Co.'s pipeline include, Xadago® (safinamide), for the treatment of Parkinson's disease (PD) and PD Levodopa-induced dyskinesia; Sarizotan, for the treatment of Rett syndrome (Orphan drug status); Evenamide (NW-3509), for the treatment of Schizophrenia and Clozapine-treatment-resistant schizophrenia; and Ralfinamide for patients with specific rare pain indications (neuropathic pain).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.